Product Information
SKYRIZI 150 MG/ML PEN is a brand product labeled by AbbVie Inc., priced at $22774.3609 per ML under NDC 00074210001. Its NADAC has been published 202 times since Nov 23, 2022.
Strength
150 mg/mL
Manufacturer
AbbVie Inc.NDC
00074210001
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
RISANKIZUMABApproval Type
Biologic (BLA)
FDA Application
BLA761105On Market Since
4/26/2021
Pharmacological Classes
Price Statistics
The NADAC for SKYRIZI 150 MG/ML PEN has been published 202 times since Nov 23, 2022, and over the history we have for it it has risen 28.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $22774.3609 per ML |
|---|---|
| All-time high | $22807.6858 (May 13, 2026) |
| All-time low | $17642.3820 (Dec 21, 2022) |
| 52-week high | $22807.6858 |
| 52-week low | $21408.4649 |
| Median price | $20292.2678 |
| Average price | $20650.5963 |
| Largest weekly change | +8.0% (Jan 11, 2023) |
| Weeks tracked | 202 |
| Tracking since | Nov 23, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
risankizumab-rzaa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-23 Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SKYRIZI 150 MG/ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for SKYRIZI 150 MG/ML PEN, manufactured by AbbVie Inc., is $22774.3609 per ML (NDC 00074210001), effective Sep 30, 2026.
How has the price of SKYRIZI 150 MG/ML PEN changed over time?
Over the history we have for it, the NADAC for SKYRIZI 150 MG/ML PEN has risen 28.7%. It has been tracked across 202 weekly CMS publications since Nov 23, 2022.
What are the highest and lowest recorded NADAC prices for SKYRIZI 150 MG/ML PEN?
Since Nov 23, 2022, the NADAC for SKYRIZI 150 MG/ML PEN has ranged from a low of $17642.3820 (Dec 21, 2022) to a high of $22807.6858 (May 13, 2026), with a median of $20292.2678 per ML.
Are there cheaper alternatives to SKYRIZI 150 MG/ML PEN?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SKYRIZI 150 MG/ML PEN in a comparable dosage form, but none are currently priced below it.
Who manufactures SKYRIZI 150 MG/ML PEN?
SKYRIZI 150 MG/ML PEN (NDC 00074210001) is labeled by AbbVie Inc., and CMS classifies it as a brand product.